Form 4: Organogenesis Holdings Inc. Executive Granted Stock Options and Restricted Stock Units

Antonio S. Montecalvo, Vice President of Health Policy at Organogenesis Holdings Inc., received stock options and restricted stock units (RSUs) on February 19, 2025, according to a Form 4 filing.

Summary

• Antonio S. Montecalvo, Vice President of Health Policy at Organogenesis Holdings Inc., was granted 43,956 stock options and 42,493 restricted stock units (RSUs) on February 19, 2025.
• The stock options have an exercise price of $3.53 and become exercisable in equal annual installments over four years, beginning February 15, 2025, and expire on February 19, 2035.
• The RSUs vest in equal annual installments over four years, beginning February 15, 2025, with each RSU representing the right to receive one share of Organogenesis Class A common stock upon vesting.
• Following the reported transaction, Montecalvo directly owns 43,956 derivative securities and beneficially owns 196,680 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity suggests confidence in the executive and the company's future prospects, but it's a routine transaction.

Positives

• The grant of stock options and RSUs aligns Montecalvo's interests with those of the shareholders, incentivizing him to contribute to the company's success.
• The vesting schedules of both the options and RSUs (four years) encourage long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued growth and value creation.

Industry Context

Equity grants are a common practice in the biotechnology and healthcare industries to attract, retain, and incentivize key executives. The terms of the grants (vesting schedule, exercise price) are typically designed to align executive compensation with shareholder value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation tools for executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules of four years are typical to ensure long-term alignment of interests.
• The specific value of the grants would need to be compared to peer companies to assess whether the compensation is competitive and reasonable.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with long-term value creation.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Organogenesis Holdings Inc., Antonio S. Montecalvo, stock options, restricted stock units, RSUs, Form 4, equity incentive plan, Class A common stock, beneficial ownership, executive compensation